New insights on disintegrin-receptor interactions: Eristostatin and melanoma cells

Mary Ann McLane, M. A. Kuchar, C. Brando, D. Santoli, C. A. Paquette-Straub, Mary Beth Miele

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Viper venom disintegrins have been used frequently to study the cellular receptors which characterize various types of cells, including platelets, endothelial cells and cancer cells. While the majority of such analyses have pointed to involvement of integrin receptors αvβ3, α5β1 or αIIbβ3, this may not always be so. Eristostatin, from Eristocophis macmahoni, is a potent inhibitor of ADP-induced platelet aggregation as well as of human and murine melanoma metastases in mouse model systems. This disintegrin requires an RGDW motif, as well as an intact C-terminus, in order to interact with both platelets and four different types of melanoma cells. Eristostatin causes nonmetastatic SBc12 melanoma cells to show higher susceptibility to specific killing by NK-like TALL-104 cells. While it is known that eristostatin binds to αIIbβ3 on platelets, the receptor with which eristostatin binds to the melanoma cells has not yet been identified.

Original languageEnglish (US)
Pages (from-to)177-182
Number of pages6
Issue number3-6
StatePublished - 2001

All Science Journal Classification (ASJC) codes

  • Hematology


Dive into the research topics of 'New insights on disintegrin-receptor interactions: Eristostatin and melanoma cells'. Together they form a unique fingerprint.

Cite this